Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Evidera has entered into an agreement to acquire Medimix International, a technology company providing RWE insights and information to the pharmaceutical, diagnostic and medical device industries.
read more
evitria AG, a global antibody expression service provider located in Zurich, Switzerland, has entered into a non-exclusive bYlok® bispecific pairing technology license agreement with Lonza. Lonza’s bYlok® technology redefines IgG-like bispecific ...
read more
Tuesday, December 03, 2024
Sapio Sciences announced that evitria, a provider of antibody expression services, has selected Sapio’s Electronic Lab Notebook (ELN) and Sapio Report Builder to enhance its sample tracking, data capture, and reporting capabilities.
read more
Evoke Pharma announced that it has entered into an agreement with Rho, Inc., a regulatory consulting and contract research organization.
read more
EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the appointment of Colin McCracken as Chief Executive Officer with immediate effect.
read more
EVONETIX, a synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted a European patent covering its unique Binary Assembly method for gene synthesis.
read more
Friday, September 11, 2020
The companies will work together on the advancement and commercial scale-up of Evonetix’s proprietary MEMS-based silicon chips and accelerate the development of Evonetix’s first product, a DNA desktop writer.
read more
Wednesday, August 04, 2021
Evonik has acquired German biotech company JeNaCell. The acquisition expands Evonik’s biomaterials portfolio to provide biotechnologically derived cellulose. The nature-identical material developed by JeNaCell is used in medical technology and ...
read more
Monday, November 17, 2025
Evonik has entered a strategic partnership with InVitria to supply animal component-free (ACF) recombinant human serum albumin to the global biopharmaceutical industry.
read more
Evonik entered into a long-term supply agreement with Phathom Pharmaceuticals. Through the agreement Evonik will produce large-scale volumes of vonoprazan at its FDA-inspected manufacturing sites in Tippecanoe, Indiana, USA and Dossenheim, Germany.
read more
Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs). This polymer-based platform complements Evonik’s existing portfolio of lipid-based drug ...
read more
Thursday, August 04, 2022
Evonik is building a new cGMP facility to manufacture lipids for clinical development and launch of innovative medicines. The new cGMP lipid launch facility is located in Hanau, Germany and will provide customers with smaller batch sizes of lipids as...
read more
Evonik has closed its previously announced acquisition of the LACTEL Absorbable Polymers product line from DURECT on December 31, 2020.
read more
Wednesday, August 14, 2024
Evonik is collaborating with KNAUER Wissenschaftliche Geräte GmbH, a manufacturer of scientific instruments, to improve the upscaling of lipid nanoparticle (LNP) formulations. By combining Evonik’s formulation and scale-up expertise with KNAUER’s ...
read more
Wednesday, February 17, 2021
Evonik has announced an investment in short-term expansion of its specialty lipids production which are needed for mRNA-based COVID-19 vaccines.
read more